Tolerability and safety of reboxetine

Reviews in Contemporary Pharmacotherapy

Volumn 11, Issue 5, 2000, Pages 321-330

  Baldwin, David S ^a   Buis, Christel ^a   Carabal, Eloisa ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE;

AGITATION; CONSTIPATION; DEPRESSION; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; PARESTHESIA; REVIEW; SWEATING; TACHYCARDIA; URINARY DYSFUNCTION; VERTIGO; XEROSTOMIA;

EID: 0033910053     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anx 1998; 7 (Suppl 1): 11-17.
2. Anderson IM, Nutt DJN, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000, in press.
3. Anonymous. Reboxetine - another new antidepressant. Drug Ther Bull 1998; 36: 86-88.
4. Avenoso A, Facciolà G, Scordo MG, Spina E. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers. Ther Drug Monit 1999; 21: 577-579.
5. Baldwin DS. Adverse drug reactions to newer antidepressants. Adv Drug React Bull 2000; 200: 763-766.
6. Baldwin DS, Carabal E. Reboxetine, a selective noradrenaline reuptake inhibitor for the treatment of depression. Drugs Today 1999; 35: 719-724.
7. Baldwin DS, Hawley CJ, Szabadi E et al. Reboxetine in the treatment of depression: early clinical trial experience in the UK. Int J Psychiatry Clin Pract 1998; 2: 195-201.
8. Ban TA, Gaszner P, Aguglia E et al. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum Psychopharmacol 1998; 13 (Suppl): S29-S39.
9. Berzewski H, Van Moffaert M, Gagiano CA. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 1997; 7 (Suppl 1): S37-S47.
10. Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry 1998; 59 (Suppl 14): 4-7.
11. Chambers CD, Johnson KA, Dick LM et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-1015.
12. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16: 356-362.
13. Demyttenaere K. Compliance during treatment with antidepressants. J Affect Disord 1997; 43: 27-39.
14. Denolle T, Pellizzoni C, Jannuzzo MG, Poggesi I. Hemodynamic effects of reboxetine in healthy male volunteers. Clin Pharmacol Ther 1999; 66: 282-287.
15. Dostert P, Castelli MG, Cicioni P, Strolin Benedetti M. Reboxetine prevents the tranylcypromine-induced increase in tyramine levels in rat heart. J Neural Transm 1994; 41 (Suppl): 149-153.
16. Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997; 7 (Suppl 1): S23-S35.
17. Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997; 11 (Suppl): S17-S23.
18. Fiorentini F, Poggesi I, Jannuzzo MG, Seiberling M, Dostert P, Strolin Benedetti M. Effect of lorazepam on the pharmacokinetics of reboxetine in healthy volunteers. Eur Neuropsychopharmacol 1995; 5: 300.
19. Fleishaker JC, Herman BD, Pearson EK, Ionita A, Mucci M. Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers. Clin Drug Invest 1999; 18: 141-150.
20. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. SSRIs versus alternative antidepressants in depressive disorder (Cochrane Review). The Cochrane Library, Issue 4. Oxford: Update Software, 1999.
21. Harkin A, Kelly JP, McNamara M et al. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol 1999; 364: 123-132.
22. Herman BD, Fleishaker JC, Brown MT. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. Clin Pharmacol Ther 1999; 66: 374-379.
23. Hermann WM, Fuder H. Reboxetine, a selective noradrenaline reuptake inhibitor, is non-sedative and does not impair psychomotor performance in healthy subjects. Hum Psychopharmacol 1998; 13: 425-433.
24. Hindmarch I. The effects of antidepressants on psychomotor function with particular reference to reboxetine. Eur Neuropsychopharmacol 1997; 7 (Suppl 1): S17-S21.
25. Jannuzzo MG, Bosc M, Renoux A, Dostert P, Strolin Benedetti M. Effect of reboxetine on the pharmacokinetics of lorazepam in healthy volunteers. Eur Neuropsychopharmacol 1995; 5: 300-301.
26. Katona C, Beroff E, Chiu E, Tack P, Versiani M, Woelk H. Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. J Affect Disord 1999; 55: 203-213.
27. Kerr JS, Powell J, Hindmarch I. The effects of reboxetine and amitriptyline, with and without alcohol, on cognitive function and psychomotor performance. Br J Clin Pharmacol 1996; 42: 239-241.
28. Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction: incidence, possible aetiology and implications for management. J Psychopharmacol 1997; 11: 72-82.
29. Lejoyeux M, Ades J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatr 1997; 58 (Suppl 7): 11-16.
30. Martin RM, Hilton SR, Kerry SM, Chards NM. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. Br Med J 1997; 314: 646-651.
31. Massana J, Möller H-J, Burrows GD, Montenegro RM. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999; 14: 73-80.
32. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997; 11 (Suppl): S9-S15.
33. Montgomery SA, Henry J, McDonald G et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47-53.
34. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997; 11: (Suppl): S33-S37.
35. Nulman I, Rovet J, Stewart DE et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258-262.
36. Ray WA. Psychotropic drugs and injuries among the elderly: a review. J Clin Psychopharmacol 1992; 12: 382-386.
37. Szabadi E. Doxazosin for reboxetine-induced urinary hesitancy. Br J Psychiatry 1998; 173: 441-442.
38. Szabadi E, Bradshaw CM, Boston PF, Langley RW. The human pharmacology of reboxetine. Hum Psychopharmacol 1998; 13: S3-S12.
39. Theofilopoulos N, McDade G, Szabadi E, Bradshaw CM. Effects of reboxetine and desipramine on the kinetics of the pupillary light reflex. Br J Clin Pharmacol 1995; 39: 251-255.
40. Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R. Reboxetine, a unique selective NRI. prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999; 60: 400-406.
41. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in patients with severe major depressive disorder. J Clin Psychopharmacol 2000; 20: 28-34.
42. Warrington SJ, Padgham C, Lader M. The cardiovascular effects of antidepressants. Psychological Medicine Monograph Supplement 16. Cambridge: Cambridge University Press, 1989.
43. Wienkers LC, Allievi C, Hauer MJ, Wynalda MA. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos 1999; 27: 1334-1340.